Published in Am Heart J on August 27, 2013
Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J (2014) 1.74
Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. Eur Heart J (2015) 0.83
Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. Int J Cardiol (2015) 0.79
Role of coronary physiology in the contemporary management of coronary artery disease. World J Clin Cases (2015) 0.75
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med (1996) 5.93
Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol (2010) 5.63
Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol (2007) 5.02
Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med (2006) 4.37
A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet (2005) 3.10
Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med (1996) 2.55
Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med (1984) 2.34
Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med (1994) 2.10
Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv (2010) 2.06
Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation (2010) 1.92
Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2008) 1.85
Whither trial-based economic evaluation for health care decision making? Health Econ (2006) 1.73
Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome. J Am Coll Cardiol (2003) 1.68
Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. Am Heart J (2001) 1.62
Fractional flow reserve in patients with prior myocardial infarction. Circulation (2001) 1.37
Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation (2002) 1.19
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J (2004) 1.19
Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation (2003) 1.09
Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in ST-Elevation Myocardial Infarction. J Am Heart Assoc (2012) 1.08
Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes (2009) 1.07
Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv (2011) 1.06
Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 1.05
Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv (2013) 0.98
High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol (2008) 0.95
Quantitative relation between hemodynamic changes during intravenous adenosine infusion and the magnitude of coronary hyperemia: implications for myocardial perfusion imaging. J Am Coll Cardiol (2005) 0.92
Usefulness of fractional flow reserve measurements to defer revascularization in patients with stable or unstable angina pectoris, non-ST-elevation and ST-elevation acute myocardial infarction, or atypical chest pain. Am J Cardiol (2006) 0.91
Usefulness of fractional flow reserve to improve diagnostic efficiency in patients with non-ST elevation myocardial infarction. Am J Cardiol (2012) 0.90
Usefulness of hemodynamic changes during adenosine infusion in predicting the diagnostic accuracy of adenosine technetium-99m sestamibi single-photon emission computed tomography (SPECT). Am J Cardiol (1997) 0.87
Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement. Catheter Cardiovasc Interv (2004) 0.86
Caffeine abstinence augments the systolic blood pressure response to adenosine in humans. Am J Cardiol (1998) 0.84
The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int J Cardiol (2012) 0.83
Angiographic core laboratory reproducibility analyses: implications for planning clinical trials using coronary angiography and left ventriculography end-points. Int J Cardiovasc Imaging (2007) 0.82
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med (2013) 11.03
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med (2012) 8.39
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol (2010) 5.63
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med (2005) 4.45
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health (2013) 4.22
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Outcomes of elective induction of labour compared with expectant management: population based study. BMJ (2012) 3.07
Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J (2009) 3.02
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ (2002) 3.00
Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation (2013) 2.98
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol (2010) 2.89
Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study. BMJ (2002) 2.89
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens (2010) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A (2003) 2.43
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol (2005) 2.43
Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med (2013) 2.37
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet (2006) 2.25
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics (2013) 2.21
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ (2013) 2.21
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation (2011) 2.17
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart (2011) 2.17
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet (2011) 2.16
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health (2012) 2.14
Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health (2008) 2.14
Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv (2011) 2.08
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil (2010) 1.98
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol (2012) 1.94
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health (2013) 1.89
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev (2005) 1.82
Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. Circ Cardiovasc Imaging (2011) 1.80
Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ (2003) 1.76
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J (2010) 1.69
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. Int J Epidemiol (2012) 1.67
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care (2013) 1.66
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making (2012) 1.61
Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol (2008) 1.59
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2014) 1.59
Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Heart J (2007) 1.57
Early management of unstable angina and non-ST-segment elevation myocardial infarction: summary of NICE guidance. Heart (2010) 1.56
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J (2012) 1.55
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med (2009) 1.54
Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation (2010) 1.54
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Clin Ther (2013) 1.53
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol (2010) 1.51
Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics (2002) 1.51
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. J Med Econ (2013) 1.49
Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol (2009) 1.47
25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis (2012) 1.46
Importance of collateral circulation in coronary heart disease. Eur Heart J (2007) 1.45
Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol (2014) 1.45
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med (2013) 1.44
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation (2007) 1.43
N-terminal pro-brain natriuretic peptide and cognitive decline in older adults at high cardiovascular risk. Ann Neurol (2014) 1.41
Observational studies of drug-eluting stents--some are more equal than others. EuroIntervention (2009) 1.41
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice): a multicenter study in consecutive patients. J Am Coll Cardiol (2013) 1.38
Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ (2004) 1.37
Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation (2009) 1.36